SIMPLIFY PROPEL OPPORTUNITIES ETF (SURI) News

Compass Pathways Announces U.S. Healthcare Provider Grant Program Recipients To Create Training For Delivery Of Psychedelic Treatments

These programs are intended to address both the need for foundational training in psychedelics, as well as ensuring HCPs are well-prepared to care for patients receiving treatment with COMP360

BenzingaSep 10 18:41

Compass Pathways' Psilocybin Treatment Shows Lasting Benefits in Treatment-Resistant Depression

Compass Pathways plc (NASDAQ:CMPS) on Wednesday shared topline 52-week Part C results from its Phase 3 COMP005 study evaluating COMP360, a proprietary synthetic formulation of psilocybin, for

BenzingaSep 10 01:18

Oil Tops $100: Ten Oil Stocks With the Strongest Quant Ratings

Seeking AlphaSep 9 21:49

Compass Pathways Shares Topline 52-week Results (Part C) From Its Phase 3 COMP005 Trial Of Comp360 For Treatment-Resistant Depression, Showing Additional Benefit Extending Durability Out To 1 Year

Notable additional benefit observed with an added reduction in MADRS1 score leading to an average 13-point reduction from baseline at Week 52 with durability extended out to 1 year for participants

BenzingaSep 9 18:37

'FDA's Acting Drug, Vaccine Regulators Tapped for Permanent Roles'- Bloomberg

'FDA's Acting Drug, Vaccine Regulators Tapped for Permanent Roles'-

BenzingaSep 9 04:20

Ten Energy Stocks Combining Strong Revenue Growth With Attractive Valuations

Seeking AlphaSep 8 18:57

Compass Pathways To Participate In Psych Congress 2026 With New Educational Campaign Regarding Treatment-Resistant Depression

Congress taking place in New Orleans, LA, from September 14-19. The Company will debut Change the Tune in TRD, a new educational campaign for U.S. HCPs focused on TRD, and present new HEOR data

BenzingaSep 8 18:36

The Trade Desk to Leave S&P 500 as Bloom Energy, Everpure, Illumina Join Index

Seeking AlphaSep 6 21:15

Bloom Energy Surges on Inclusion to S&P 500; Illumina, Everpure Also Added

Seeking AlphaSep 5 06:20

JP Morgan Maintains Neutral on Plains GP Holdings, Raises Price Target to $27

JP Morgan analyst Jeremy Tonet maintains Plains GP Holdings (NASDAQ:PAGP) with a Neutral and raises the price target from $24 to $27.

BenzingaSep 4 05:07

HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $8 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and maintains $8 price target.

BenzingaSep 3 23:54

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In Q3

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock's strength on days when prices go

BenzingaSep 3 18:09

Milestone Pharmaceuticals Announces First Patient Enrolled In Phase 3 Trial Of Etripamil In Approximately 150 Patients With Atrial Fibrillation With Rapid Ventricular Rate

Milestone Pharmaceuticals Announces First Patient Enrolled In Phase 3 Trial Of Etripamil In Approximately 150 Patients With Atrial Fibrillation With Rapid Ventricular

BenzingaAug 21 20:02

This Sphere Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings

BenzingaAug 20 19:51

Cantor Fitzgerald Initiates Coverage On Milestone Pharmaceuticals With Overweight Rating, Announces Price Target of $3

Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight rating and announces Price Target of $3.

BenzingaAug 20 18:32

US Stock Market Close | US Treasury intervenes to support long-term bonds, lifting all three major indices; Moderna surges, igniting a rally in the biopharmaceutical sector, with Merck & Co up over 12% and the S&P Biotechnology ETF rising nearly 6%; Bitco

The S&P 500 closed up 0.21% at 7,707.98, the Nasdaq Composite rose 0.16% to 26,331.09, and the Dow Jones Industrial Average gained 0.22% to 53,463.05, ending a three-day losing streak for all three major indices. Moderna surged 176.97% to hit a record high, while Merck & Co jumped 13%, leading the healthcare sector's gains in the S&P; meanwhile, semiconductor and AI momentum stocks suffered heavy losses, with chip ETFs falling a cumulative 7.7% over two days.

wallstreetcnAug 20 07:02

Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48

Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $56 to $48.

BenzingaAug 19 21:46

Barclays Maintains Overweight on Phathom Pharmaceuticals, Lowers Price Target to $14

Barclays analyst Glen Santangelo maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Overweight and lowers the price target from $18 to $14.

BenzingaAug 17 21:57

Corcept, Revolution Medicines Lead Ten Large-cap Healthcare Stocks Surging in 2026

Seeking AlphaAug 17 20:26

This Vail Resorts Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings

BenzingaAug 14 00:11